The OSI’s Strategic Advisory Board recently attended #CTOS23 with experts from around the globe, where OSI grant winner Isidro Cortés-Ciriano, PhD, was featured. Learn more about his osteosarcoma study: osinst.org/our-work/#work @emblebi @isidrolauscher

Congratulations are in order to our Head of Cohorts Dr Mandy Ballinger, who has received the 2023 Liddy Shriver Early Career Research Award at #CTOS23 in Dublin. This recognition of her pioneering work marks the culmination of years dedicated to #sarcoma genetics and early detection to protect people with Li-Fraumeni syndrome (LFS). Thank you, Mandy, for your outstanding research contributions in the field of sarcoma. We wouldn’t be Team Omico without you.

I have to admit that #poster session was really cool during #CTOS #CTOS23 😃🥂 Loooking foreward for next meeting already 💙💚💛

$DCPH has a new challenger. @ByMadeleineA's take on IDRx data at #CTOS23 oncologypipeline.com/apexonc… $BPMC

Last but not least - our poster on the generation and characterization of the first patient-derived, radiation-induced breast angiosarcoma cell line. Hope it can foster future preclinical #angiosarcoma research! #sarcoma #CTOS23 @SarcomaUniTo @SilviaBrusco6 @DAmbrosio_MD

Congrats ⁦@ballingermandy⁩ on your amazing work deservedly recognized with the Liddy Shriver award #ctos23. Has been great to see this work grow in impact over the years.

Trial running in @NIO_PIB in #Warsaw just presented in #Dublin at @ctosociety meeting #CTOS23 #CTOS

High quality data (as always from ⁦@DCalleMD⁩) quantifying the benefit of surgery in high volume centre (13 cases per year) - distance from black line to red/blue line shows magnitude of benefit. #ctos23

Anticipation building in RPS session prior to presentation of first ever data from prospective RESAR registry by Dr Mark Fairweather. #ctos23

Great presentation form Dr Keila Torres of the extraordinary potential of the mass spec pen to guide intraoperative decision making in #sarcoma. #ctos23. Will be eagerly watching this space!

Great #CTOS #CTOS23 evening with Guinness 🍻

Thank you @ashleighg and program committee #CTOS2023 for organizing an incredible meeting! #ctos23

We are glad to share the first poster of @SachinSarcoma displayed in the patient advocacy lounge in Dublin Ireland in @ctosociety for the sarcoma community. We thank Dr @samdoc_mamc Sarcoma medical Oncology #AIIMS for support. Thanks @sarcomapatients 4 the opportunity #CTOS23

Fantastic work from our surgical fellow ⁦@eyal_more⁩ ⁦@PeterMacCC⁩ demonstrating that routine extended mastectomy for primary radiation induced #angiosarcoma provides very good long term disease control even without chemotherapy. #ctos23

It's the final day of the @ctosociety Annual Meeting in Dublin and it's been a hugely positive experience to learn of the work being done across the world on sarcoma. Together we are making change happen. #ctos2023 #ctos23

Strong arguments from ⁦@herbloong⁩ for off label treatment in #sarcoma given the real world lack of access to clinical trials in much of the world. #ctos23

“Access to clinical trials is a luxury…” @herbloong #CTOS23

Thank you to @sarcomapatients for hosting the advocacy lounge @ctosociety. We have been able to connect and speak with advocates in the sarcoma community #CTOS23 #Sarcoma please reach out if you would like to connect

@breelynwilkyMD -Botensilimab and balstilimab in #Sarcoma w 15-29% objective responses, 40%PF @ 6 months in #sarcoma -Overall limited toxicity -Current phase 1 study (C-800-01) is actively enrolling patients in an expansion sarcoma cohort @Agenus_Bio #CTOS2023 #ctos23

@SBonvalot arguing better outcomes for #Sarcoma surgery at high volume #Sarcoma centers citing @SylvesterCancer data @NGoelMD @JulieGrossmanMD #CTOS2023 #ctos23